Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Multiple buying at BriaCell Therapeutics (T:BCT)

Updated Wednesday Mar 21, 2018 02:04 AM EDT

William Williams, CEO and Director, acquired 645,600 Common Shares on a direct ownership basis at a price of $0.140 through a private transaction on March 19th, 2018. The insider also acquired 645,600 Warrants with an exercise price of $0.100 for 36 months. This represents a $90,384 investment into the company's shares and an account share holdings change of 6.0%.

On the same terms, Rahoul Sharan, a Director, acquired 500,000 Common Shares and 500,000 Warrants on a direct ownership basis. This represents a $70,000 investment into the company's shares and an account share holdings change of 48.1%. Saeid Babaei, a Director, acquired 150,000 Common Shares and 150,000 Warrants on a direct ownership basis. This represents a $21,000 investment into the company's shares and an account share holdings change of greater than 100%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Briacell Therapeutics Corp is a Canada-based clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The Company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT, in advanced breast cancer along with the co-development of BriaDX, its companion diagnostic. Additionally, there is a Food and Drug Administration (FDA) approved combination study of Bria-IMT with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT. Moreover, the Company is developing Bria-OTS, the first off the shelf personalized treatment for advanced stage breast cancer. Briacell Therapeutics Corp's small molecule program consists of novel, selective protein kinase C delta inhibitors that have shown activity in pre-clinical models of several cancers and fibrotic diseases.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Rain
Mixed
Mostly Sunny
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to BriaCell Therapeutics Corp. (BCT)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $BCT.CA

  • No tweets found

Stocktwits